Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Atossa Therapeutics set to join Russell 2000, Russell 3000 Indexes » 09:07
06/16/21
06/16
09:07
06/16/21
09:07
ATOS

Atossa Therapeutics

$4.61 /

-0.02 (-0.43%)

Atossa Therapeutics…

Atossa Therapeutics announced it is set to be added to the Russell 2000 and Russell 3000 Indexes. This will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, and June 14, 2021.

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

ATOS Atossa Therapeutics
$4.61 /

-0.02 (-0.43%)

Friday
Hot Stocks
Atossa Therapeutics approved by Swedish MPA to start phase 2 study on endoxifen » 09:05
06/11/21
06/11
09:05
06/11/21
09:05
ATOS

Atossa Therapeutics

$4.07 /

-0.34 (-7.72%)

Atossa Therapeutics…

Atossa Therapeutics announces that it has received approval from the Swedish Medical Product Agency, or MPA, to initiate a Phase 2 clinical study of its oral Endoxifen for the reduction of mammographic breast density, or MBD. The primary objective of the MBD study is to determine the dose-response relationship of daily oral Endoxifen on mammographic breast density reduction, with secondary endpoints assessing safety and tolerability. The Phase 2 study will be randomized, double-blinded and placebo-controlled. It will include approximately 240 pre-menopausal women with measurable MBD who will receive daily doses of oral Endoxifen or placebo for six months.

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

ATOS Atossa Therapeutics
$4.07 /

-0.34 (-7.72%)

Over a week ago
Conference/Events
Atossa Therapeutics to hold a webinar on Endoxifen » 10:55
06/09/21
06/09
10:55
06/09/21
10:55
ATOS

Atossa Therapeutics

$5.34 /

-0.72 (-11.88%)

Dr. Quay, President &…

Dr. Quay, President & CEO and CFO Guse discuss final data from the Phase 2 study of Endoxifen administered to breast cancer patients prior to surgery on a webinar to be held on June 9 at 11 am. Webcast Link

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$5.34 /

-0.72 (-11.88%)

ATOS Atossa Therapeutics
$5.34 /

-0.72 (-11.88%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$5.34 /

-0.72 (-11.88%)

ATOS Atossa Therapeutics
$5.34 /

-0.72 (-11.88%)

Conference/Events
Atossa Therapeutics to hold a webinar on Endoxifen » 09:43
06/09/21
06/09
09:43
06/09/21
09:43
ATOS

Atossa Therapeutics

$6.06 /

+ (+0.00%)

Dr. Quay, President &…

Dr. Quay, President & CEO and CFO Guse discuss final data from the Phase 2 study of Endoxifen administered to breast cancer patients prior to surgery on a webinar to be held on June 9 at 11 am. Webcast Link

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$6.06 /

+ (+0.00%)

ATOS Atossa Therapeutics
$6.06 /

+ (+0.00%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$6.06 /

+ (+0.00%)

ATOS Atossa Therapeutics
$6.06 /

+ (+0.00%)

Hot Stocks
Atossa Therapeutics announce final data from phase 2 Endoxifen study » 09:06
06/09/21
06/09
09:06
06/09/21
09:06
ATOS

Atossa Therapeutics

$6.06 /

+0.055 (+0.92%)

Atossa Therapeutics…

Atossa Therapeutics announced the following final data from its Phase 2 clinical study of oral Endoxifen administered in the "window of opportunity" between diagnosis of breast cancer and surgery. Primary Endpoint Met: Reduction in Ki-67 was achieved. Ki-67, a common measure of tumor cell activity, was reduced from an average of 25.6% at screening to 6% on the day of surgery, a 65.1% reduction. Ki-67 was reduced below 25% for all patients, which is potentially clinically meaningful because studies by others have shown that a reduction below 25% improves long term survival. Secondary Endpoints Were as Follows: Safety and tolerability: All adverse events were mild and considered related to the study drug. There were no abnormal laboratory findings and no differences in vital signs, physical examinations and ECGs. Based on these results, Endoxifen was considered safe and well tolerated in this study. No adverse events led to discontinuation of the study. Other Results: Estrogen receptor expression decreased from 100% at screening to 88.6% on the day of surgery and progesterone receptor expression increased from 84.3% at screening to 92.9% on the day of surgery. No correlation between Ki-67 expression and Endoxifen levels was observed.

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$6.06 /

+0.055 (+0.92%)

ATOS Atossa Therapeutics
$6.06 /

+0.055 (+0.92%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$6.06 /

+0.055 (+0.92%)

ATOS Atossa Therapeutics
$6.06 /

+0.055 (+0.92%)

Over a month ago
Earnings
Atossa Therapeutics reports Q1 EPS (4c), two est. (5c) » 09:18
05/14/21
05/14
09:18
05/14/21
09:18
ATOS

Atossa Therapeutics

$2.37 /

-0.095 (-3.86%)

"During the first…

"During the first quarter of 2021 we continued our two key development programs, namely our Phase 2 study of oral Endoxifen for the 'window of opportunity' between diagnosis of breast cancer and surgery and our Phase 1 study of AT-301 nasal spray for at-home use for patients recently diagnosed with COVID-19," said Dr. Steven Quay, Atossa's President and Chief Executive Officer. "In addition, we continued our ongoing expanded access program with Endoxifen in which the drug continues to be well tolerated and breast cancer recurrence has not been seen clinically. We also received an important authorization from the FDA for an additional expanded access treatment program in an ovarian cancer patient. Combined with very encouraging results in our COVID-19 program with AT-301 nasal spray, we continued to make great progress over the quarter. In the meantime, we leveraged favorable conditions in the capital markets to strengthen our balance sheet over the last few months placing Atossa in a good position to execute on these and potential additional business opportunities during the remainder of 2021. As a result, we are diligently moving our existing programs forward, while actively exploring the possibility for strategic expansion into other areas where we might see near-term milestones and results. We look forward to continuing to update our stockholders on these opportunities as they develop," concluded Dr. Quay.

ShowHide Related Items >><<
ATOS Atossa Therapeutics
$2.37 /

-0.095 (-3.86%)

ATOS Atossa Therapeutics
$2.37 /

-0.095 (-3.86%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
ATOS Atossa Therapeutics
$2.37 /

-0.095 (-3.86%)

Options
Largest borrow rate increases among liquid names » 08:45
05/14/21
05/14
08:45
05/14/21
08:45
IPOE

Social Capital Hedosophia Holdings Corp. V

$14.71 /

-0.32 (-2.13%)

, UWMC

UWM Holdings

$7.42 /

+0.05 (+0.68%)

, QS

QuantumScape

$26.62 /

-0.51 (-1.88%)

, MNMD

MindMed

$3.00 /

+0.07 (+2.39%)

, NMM

Navios Maritime Partners

$28.91 /

+0.62 (+2.19%)

, CLMT

Calumet Specialty Products

$5.49 /

-0.04 (-0.72%)

, ATOS

Atossa Therapeutics

$2.37 /

-0.095 (-3.86%)

, SAND

Sandstorm Gold

$8.06 /

-0.02 (-0.25%)

, BLNK

Blink Charging

$26.18 /

-2.64 (-9.16%)

, BGS

B&G Foods

$29.27 /

+0.575 (+2.00%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Social Capital Hedosophia V (IPOE) 114.00% +6.07, UWM Holdings Corp (UWMC) 34.88% +2.10, Quantumscape (QS) 18.95% +0.87, (MNMD) 26.15% +0.86, Navios Maritime Partners (NMM) 8.55% +0.63, Calumet Specialty Products (CLMT) 3.70% +0.39, Atossa Genetics (ATOS) 5.00% +0.39, Sandstorm Gold (SAND) 0.59% +0.28, Blink Charging (BLNK) 69.21% +0.23, and B&G Foods (BGS) 4.81% +0.18.

ShowHide Related Items >><<
UWMC UWM Holdings
$7.42 /

+0.05 (+0.68%)

SAND Sandstorm Gold
$8.06 /

-0.02 (-0.25%)

QS QuantumScape
$26.62 /

-0.51 (-1.88%)

NMM Navios Maritime Partners
$28.91 /

+0.62 (+2.19%)

MNMD MindMed
$3.00 /

+0.07 (+2.39%)

IPOE Social Capital Hedosophia Holdings Corp. V
$14.71 /

-0.32 (-2.13%)

CLMT Calumet Specialty Products
$5.49 /

-0.04 (-0.72%)

BLNK Blink Charging
$26.18 /

-2.64 (-9.16%)

BGS B&G Foods
$29.27 /

+0.575 (+2.00%)

ATOS Atossa Therapeutics
$2.37 /

-0.095 (-3.86%)

IPOE Social Capital Hedosophia Holdings Corp. V
$14.71 /

-0.32 (-2.13%)

03/17/21 Wedbush
LendingClub price target raised to $20.50 from $14 at Wedbush
UWMC UWM Holdings
$7.42 /

+0.05 (+0.68%)

04/21/21 Barclays
UWM Holdings initiated with an Overweight at Barclays
03/26/21 Credit Suisse
Credit Suisse lowers estimates on mortgage originators
02/23/21 Credit Suisse
UWM Holdings initiated with an Outperform at Credit Suisse
02/17/21 Goldman Sachs
UWM Holdings initiated with a Neutral at Goldman Sachs
QS QuantumScape
$26.62 /

-0.51 (-1.88%)

03/08/21 Cowen
Cowen bullish on battery technology, starts QuantumScape at Outperform
03/08/21 Cowen
QuantumScape initiated with an Outperform at Cowen
03/04/21 Baird
QuantumScape initiated with a Neutral at Baird
02/11/21 Morgan Stanley
QuantumScape initiated with an Overweight at Morgan Stanley
MNMD MindMed
$3.00 /

+0.07 (+2.39%)

NMM Navios Maritime Partners
$28.91 /

+0.62 (+2.19%)

02/24/21 Citi
Navios Maritime Partners price target raised to $21 from $7.50 at Citi
01/29/21 Janney Montgomery Scott
Navios Maritime Partners price target raised to $20 from $15 at Janney Montgomery Scott
01/08/21 Jefferies
Navios Maritime Partners upgraded to Buy, price target doubled at Jefferies
01/08/21 Jefferies
Navios Maritime Partners upgraded to Buy from Hold at Jefferies
CLMT Calumet Specialty Products
$5.49 /

-0.04 (-0.72%)

03/24/21 Wells Fargo
Calumet Specialty Products upgraded to Overweight at Wells Fargo
03/24/21 Wells Fargo
Calumet Specialty upgraded to Overweight from Equal Weight at Wells Fargo
12/15/20 Wells Fargo
Calumet Specialty Products downgraded to Equal Weight at Wells Fargo
12/15/20 Wells Fargo
Calumet Specialty downgraded to Equal Weight from Overweight at Wells Fargo
ATOS Atossa Therapeutics
$2.37 /

-0.095 (-3.86%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
SAND Sandstorm Gold
$8.06 /

-0.02 (-0.25%)

02/12/21 National Bank
Sandstorm Gold price target lowered to C$13.50 from C$14.25 at National Bank
02/08/21 CIBC
Sandstorm Gold price target lowered to C$13.50 from C$16.75 at CIBC
01/11/21 National Bank
Sandstorm Gold price target lowered to C$14.25 from C$15.50 at National Bank
12/16/20 Roth Capital
Sandstorm Gold initiated with a Buy at Roth Capital
BLNK Blink Charging
$26.18 /

-2.64 (-9.16%)

05/11/21
Fly Intel: Top five analyst initiations
05/11/21 Needham
Blink Charging initiated with a Buy at Needham
05/10/21 Needham
Blink Charging initiated with a Buy at Needham
03/08/21 Cowen
Blink Charging initiated with an Outperform at Cowen
BGS B&G Foods
$29.27 /

+0.575 (+2.00%)

03/22/21
Fly Intel: Top five analyst downgrades
03/22/21 Piper Sandler
B&G Foods downgraded to Neutral from Overweight at Piper Sandler
03/03/21 RBC Capital
B&G Foods price target lowered to $29 from $32 at RBC Capital
01/19/21 Stephens
B&G Foods initiated with an Equal Weight at Stephens
SAND Sandstorm Gold
$8.06 /

-0.02 (-0.25%)

QS QuantumScape
$26.62 /

-0.51 (-1.88%)

NMM Navios Maritime Partners
$28.91 /

+0.62 (+2.19%)

CLMT Calumet Specialty Products
$5.49 /

-0.04 (-0.72%)

BLNK Blink Charging
$26.18 /

-2.64 (-9.16%)

BGS B&G Foods
$29.27 /

+0.575 (+2.00%)

  • 25
    Mar
  • 08
    Jan
QS QuantumScape
$26.62 /

-0.51 (-1.88%)

IPOE Social Capital Hedosophia Holdings Corp. V
$14.71 /

-0.32 (-2.13%)

BLNK Blink Charging
$26.18 /

-2.64 (-9.16%)

QS QuantumScape
$26.62 /

-0.51 (-1.88%)

IPOE Social Capital Hedosophia Holdings Corp. V
$14.71 /

-0.32 (-2.13%)

CLMT Calumet Specialty Products
$5.49 /

-0.04 (-0.72%)

BLNK Blink Charging
$26.18 /

-2.64 (-9.16%)

BGS B&G Foods
$29.27 /

+0.575 (+2.00%)

UWMC UWM Holdings
$7.42 /

+0.05 (+0.68%)

SAND Sandstorm Gold
$8.06 /

-0.02 (-0.25%)

QS QuantumScape
$26.62 /

-0.51 (-1.88%)

NMM Navios Maritime Partners
$28.91 /

+0.62 (+2.19%)

MNMD MindMed
$3.00 /

+0.07 (+2.39%)

IPOE Social Capital Hedosophia Holdings Corp. V
$14.71 /

-0.32 (-2.13%)

CLMT Calumet Specialty Products
$5.49 /

-0.04 (-0.72%)

BLNK Blink Charging
$26.18 /

-2.64 (-9.16%)

BGS B&G Foods
$29.27 /

+0.575 (+2.00%)

ATOS Atossa Therapeutics
$2.37 /

-0.095 (-3.86%)

Options
Unusually active option classes on open May 11th » 09:40
05/11/21
05/11
09:40
05/11/21
09:40
SLB

Schlumberger

$31.63 /

+ (+0.00%)

, SQQQ

ProShares UltraPro Short QQQ

$12.09 /

+ (+0.00%)

, MT

ArcelorMittal

$32.72 /

+ (+0.00%)

, BP

BP

$26.64 /

+ (+0.00%)

, PLTR

Palantir

$18.47 /

+ (+0.00%)

, UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$4.31 /

+ (+0.00%)

, DIA

SPDR Dow Jones Industrial Average ETF Trust

$347.74 /

+0.01 (+0.00%)

, IWM

iShares Trust Russell 2000 Index Fund

$219.61 /

+ (+0.00%)

, ATOS

Atossa Therapeutics

$2.77 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Schlumberger (SLB), ProShares UltraPro Short QQQ (SQQQ), ArcelorMittal (MT), BP (BP), Palantir Technologies (PLTR), ProShares Ultra VIX Short Term Futures (UVXY), SPDR DJIA ETF (DIA), iShares Russell 2000 ETF (IWM), ProShares UltraPro Short S&P 500 (SPXU), and Atossa Genetics (ATOS).

ShowHide Related Items >><<
SLB Schlumberger
$31.63 /

+ (+0.00%)

PLTR Palantir
$18.47 /

+ (+0.00%)

MT ArcelorMittal
$32.72 /

+ (+0.00%)

BP BP
$26.64 /

+ (+0.00%)

ATOS Atossa Therapeutics
$2.77 /

+ (+0.00%)

SLB Schlumberger
$31.63 /

+ (+0.00%)

05/03/21 Barclays
Schlumberger price target raised to $37 from $35 at Barclays
04/26/21 Stephens
Stephens upgrades Schlumberger ahead of 'demand-led upcycle'
04/26/21 Stephens
Schlumberger upgraded to Overweight from Equal Weight at Stephens
04/26/21 Susquehanna
Schlumberger recovery continues industry momentum, says Susquehanna
SQQQ ProShares UltraPro Short QQQ
$12.09 /

+ (+0.00%)

MT ArcelorMittal
$32.72 /

+ (+0.00%)

05/07/21 Deutsche Bank
ArcelorMittal price target raised to EUR 32 from EUR 30 at Deutsche Bank
05/07/21 Citi
ArcelorMittal price target raised to EUR 36 from EUR 17.50 at Citi
04/15/21 JPMorgan
ArcelorMittal price target raised to EUR 29.50 from EUR 26.50 at JPMorgan
04/13/21 Deutsche Bank
ArcelorMittal price target raised to EUR 30 from EUR 24 at Deutsche Bank
BP BP
$26.64 /

+ (+0.00%)

04/30/21 Berenberg
BP price target raised to 285 GBp from 280 GBp at Berenberg
04/28/21 Societe Generale
BP price target raised to 365 GBp from 360 GBp at Societe Generale
04/20/21 Deutsche Bank
BP initiated with a Hold at Deutsche Bank
04/16/21 HSBC
BP upgraded to Buy from Hold at HSBC
PLTR Palantir
$18.47 /

+ (+0.00%)

04/22/21 Wolfe Research
Palantir initiated with a Peer Perform at Wolfe Research
03/15/21 Credit Suisse
Palantir assumed with an Underperform at Credit Suisse
02/17/21
Fly Intel: Top five analyst upgrades
02/17/21 RBC Capital
Palantir price target raised to $27 from $15 at RBC Capital
UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$4.31 /

+ (+0.00%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$347.74 /

+0.01 (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$219.61 /

+ (+0.00%)

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
ATOS Atossa Therapeutics
$2.77 /

+ (+0.00%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
SLB Schlumberger
$31.63 /

+ (+0.00%)

PLTR Palantir
$18.47 /

+ (+0.00%)

BP BP
$26.64 /

+ (+0.00%)

  • 12
    May
SLB Schlumberger
$31.63 /

+ (+0.00%)

PLTR Palantir
$18.47 /

+ (+0.00%)

MT ArcelorMittal
$32.72 /

+ (+0.00%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$347.74 /

+0.01 (+0.00%)

BP BP
$26.64 /

+ (+0.00%)

SLB Schlumberger
$31.63 /

+ (+0.00%)

PLTR Palantir
$18.47 /

+ (+0.00%)

UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$4.31 /

+ (+0.00%)

SQQQ ProShares UltraPro Short QQQ
$12.09 /

+ (+0.00%)

SLB Schlumberger
$31.63 /

+ (+0.00%)

PLTR Palantir
$18.47 /

+ (+0.00%)

MT ArcelorMittal
$32.72 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$219.61 /

+ (+0.00%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$347.74 /

+0.01 (+0.00%)

BP BP
$26.64 /

+ (+0.00%)

ATOS Atossa Therapeutics
$2.77 /

+ (+0.00%)

IWM iShares Trust Russell 2000 Index Fund
$219.61 /

+ (+0.00%)

DIA SPDR Dow Jones Industrial Average ETF Trust
$347.74 /

+0.01 (+0.00%)

Options
Largest borrow rate increases among liquid names » 08:45
05/05/21
05/05
08:45
05/05/21
08:45
IPOE

Social Capital Hedosophia Holdings Corp. V

$16.17 /

-0.28 (-1.70%)

, ATOS

Atossa Therapeutics

$2.31 /

-0.16 (-6.48%)

, SKLZ

Skillz

$16.94 /

+0.405 (+2.45%)

, XL

XL Fleet

$6.41 /

-0.14 (-2.14%)

, TRIT

Triterras

$6.96 /

-0.095 (-1.35%)

, NKLA

Nikola

$10.81 /

-0.22 (-1.99%)

, WPG

Washington Prime

$2.30 /

-0.08 (-3.36%)

, MOGO

Mogo

$8.18 /

-0.38 (-4.44%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Social Capital Hedosophia V (IPOE) 113.55% +24.20, Atossa Genetics (ATOS) 3.94% +0.60, Global X Uranium (URA) 2.72% +0.57, Advisorshares Pure Us Cannabis ETF (MSOS) 3.46% +0.51, Skillz (SKLZ) 4.19% +0.48, XL Fleet (XL) 8.90% +0.42, Triterras Inc (TRIT) 49.67% +0.39, Nikola (NKLA) 33.91% +0.39, Washington Prime (WPG) 10.84% +0.35, and Mogo (MOGO) 18.26% +0.34.

ShowHide Related Items >><<
XL XL Fleet
$6.41 /

-0.14 (-2.14%)

WPG Washington Prime
$2.30 /

-0.08 (-3.36%)

TRIT Triterras
$6.96 /

-0.095 (-1.35%)

SKLZ Skillz
$16.94 /

+0.405 (+2.45%)

NKLA Nikola
$10.81 /

-0.22 (-1.99%)

MOGO Mogo
$8.18 /

-0.38 (-4.44%)

IPOE Social Capital Hedosophia Holdings Corp. V
$16.17 /

-0.28 (-1.70%)

ATOS Atossa Therapeutics
$2.31 /

-0.16 (-6.48%)

IPOE Social Capital Hedosophia Holdings Corp. V
$16.17 /

-0.28 (-1.70%)

03/17/21 Wedbush
LendingClub price target raised to $20.50 from $14 at Wedbush
ATOS Atossa Therapeutics
$2.31 /

-0.16 (-6.48%)

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
SKLZ Skillz
$16.94 /

+0.405 (+2.45%)

05/05/21 Canaccord
Skillz price target lowered to $30 from $33 at Canaccord
05/05/21 Canaccord
Skillz price target lowered to $30 from $33 at Canaccord
04/22/21 Jefferies
Skillz initiated with a Hold at Jefferies
03/25/21 Stifel
Skillz price target lowered to $28 from $30 at Stifel
XL XL Fleet
$6.41 /

-0.14 (-2.14%)

04/01/21 Canaccord
XL Fleet price target lowered to $10 from $30 at Canaccord
04/01/21 BTIG
XL Fleet price target lowered to $23 from $30 at BTIG
01/29/21 Canaccord
Canaccord sees XL Fleet going to $30 per share on 'first-mover' advantage
01/29/21 Canaccord
XL Fleet initiated with a Buy at Canaccord
TRIT Triterras
$6.96 /

-0.095 (-1.35%)

02/01/21 Oppenheimer
Triterras downgraded to Perform at Oppenheimer due to volatility, uncertainty
02/01/21 Oppenheimer
Triterras downgraded to Perform from Outperform at Oppenheimer
01/26/21 B. Riley
Triterras price target lowered to $12 from $16 at B. Riley Securities
01/22/21 Northland
Triterras downgraded to Market Perform from Outperform at Northland
NKLA Nikola
$10.81 /

-0.22 (-1.99%)

04/19/21 Wedbush
Nikola price target lowered to $13 from $25 at Wedbush
03/26/21 Vertical Research
Nikola initiated with a Buy at Vertical Research
03/18/21 Deutsche Bank
Deutsche concerned about capital raises, Tesla competition for Nikola
03/05/21
Fly Intel: Top five analyst downgrades
WPG Washington Prime
$2.30 /

-0.08 (-3.36%)

04/06/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
04/05/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
02/16/21 Truist
Washington Prime coupon non-payment part of negotiating process, says Truist
02/01/21 Truist
Macerich Q4 results 'weak,' but not much worse than expected, says Truist
MOGO Mogo
$8.18 /

-0.38 (-4.44%)

03/24/21 Canaccord
Mogo price target raised to C$14 from C$13 at Canaccord
03/23/21 H.C. Wainwright
Outlook, Moka deal should 'drive excitement' about Mogo, says H.C. Wainwright
03/01/21 H.C. Wainwright
Mogo price target raised to $16 from $4 at H.C. Wainwright
02/11/21 Canaccord
Mogo downgraded to Hold from Speculative Buy at Canaccord
XL XL Fleet
$6.41 /

-0.14 (-2.14%)

WPG Washington Prime
$2.30 /

-0.08 (-3.36%)

TRIT Triterras
$6.96 /

-0.095 (-1.35%)

SKLZ Skillz
$16.94 /

+0.405 (+2.45%)

NKLA Nikola
$10.81 /

-0.22 (-1.99%)

  • 19
    Mar
XL XL Fleet
$6.41 /

-0.14 (-2.14%)

WPG Washington Prime
$2.30 /

-0.08 (-3.36%)

TRIT Triterras
$6.96 /

-0.095 (-1.35%)

SKLZ Skillz
$16.94 /

+0.405 (+2.45%)

NKLA Nikola
$10.81 /

-0.22 (-1.99%)

IPOE Social Capital Hedosophia Holdings Corp. V
$16.17 /

-0.28 (-1.70%)

XL XL Fleet
$6.41 /

-0.14 (-2.14%)

TRIT Triterras
$6.96 /

-0.095 (-1.35%)

SKLZ Skillz
$16.94 /

+0.405 (+2.45%)

NKLA Nikola
$10.81 /

-0.22 (-1.99%)

IPOE Social Capital Hedosophia Holdings Corp. V
$16.17 /

-0.28 (-1.70%)

XL XL Fleet
$6.41 /

-0.14 (-2.14%)

WPG Washington Prime
$2.30 /

-0.08 (-3.36%)

TRIT Triterras
$6.96 /

-0.095 (-1.35%)

SKLZ Skillz
$16.94 /

+0.405 (+2.45%)

NKLA Nikola
$10.81 /

-0.22 (-1.99%)

MOGO Mogo
$8.18 /

-0.38 (-4.44%)

IPOE Social Capital Hedosophia Holdings Corp. V
$16.17 /

-0.28 (-1.70%)

ATOS Atossa Therapeutics
$2.31 /

-0.16 (-6.48%)

Options
Unusually active option classes on open May 4th » 09:40
05/04/21
05/04
09:40
05/04/21
09:40
UNVR

Univar

/

+

, YUM

Yum! Brands

/

+

, ATOS

Atossa Therapeutics

/

+

, PFE

Pfizer

/

+

, RKT

Rocket Companies

/

+

, CLF

Cleveland-Cliffs

/

+

, TDOC

Teladoc

/

+

, TWTR

Twitter

/

+

, X

U.S. Steel

/

+

, SQQQ

ProShares UltraPro Short QQQ

/

+

Unusual total active…

Unusual total active option classes on open include: Univar (UNVR), Yum! Brands (YUM), Atossa Genetics (ATOS), Pfizer (PFE), Rocket Companies (RKT), Cleveland-Cliffs (CLF), Teladoc (TDOC), Twitter (TWTR), US Steel (X), and ProShares UltraPro Short QQQ (SQQQ).

ShowHide Related Items >><<
YUM Yum! Brands
/

+

X U.S. Steel
/

+

UNVR Univar
/

+

TWTR Twitter
/

+

TDOC Teladoc
/

+

RKT Rocket Companies
/

+

PFE Pfizer
/

+

CLF Cleveland-Cliffs
/

+

ATOS Atossa Therapeutics
/

+

UNVR Univar
/

+

03/08/21 BofA
Univar downgraded to Underperform from Buy at BofA
11/06/20 Goldman Sachs
Univar downgraded to Neutral from Buy at Goldman Sachs
YUM Yum! Brands
/

+

04/29/21 BMO Capital
Yum! Brands price target raised to $120 from $105 at BMO Capital
04/29/21 Credit Suisse
Yum! Brands price target raised to $120 from $108 at Credit Suisse
04/29/21 Oppenheimer
Yum! Brands price target raised to $135 from $120 at Oppenheimer
04/29/21 Baird
Yum! Brands price target raised to $130 from $127 at Baird
ATOS Atossa Therapeutics
/

+

09/17/20 Ascendiant
Ascendiant starts Atossa Therapeutics with Buy rating, $7 price target
09/17/20 Ascendiant
Atossa Therapeutics initiated with a Buy at Ascendiant
07/17/20 Maxim
Atossa Therapeutics price target raised to $8 from $4 at Maxim
07/16/20 Maxim
Maxim doubles Atossa price target to $8 on positive COVID data
PFE Pfizer
/

+

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
RKT Rocket Companies
/

+

04/21/21
Fly Intel: Top five analyst downgrades
04/21/21 BofA
Rocket Companies downgraded to Neutral from Buy at BofA
04/05/21 Cowen
Risk to mortgage servicers rises as CFPB proposes foreclosure policy, says Cowen
03/26/21 Credit Suisse
Credit Suisse lowers estimates on mortgage originators
CLF Cleveland-Cliffs
/

+

05/04/21 Credit Suisse
Cleveland-Cliffs upgraded to Outperform from Neutral at Credit Suisse
05/04/21 Credit Suisse
Cleveland-Cliffs upgraded to Outperform from Neutral at Credit Suisse
04/30/21 B. Riley
Cleveland-Cliffs price target raised to $33 from $24 at B. Riley
04/26/21 B. Riley
Cleveland-Cliffs price target raised to $24 from $22 at B. Riley
TDOC Teladoc
/

+

05/04/21 Piper Sandler
Teladoc closed down 5% on three year old 'news,' says Piper Sandler
05/03/21 Credit Suisse
Teladoc's loss of PepsiCo contract 'old news,' says Credit Suisse
05/03/21 Cantor Fitzgerald
Teladoc competitive loss a gain for Amwell, says Cantor Fitzgerald
04/29/21 KeyBanc
Teladoc price target lowered to $220 from $270 at KeyBanc
TWTR Twitter
/

+

05/03/21 BMO Capital
Twitter price target lowered to $65 from $80 at BMO Capital
04/30/21 MKM Partners
Twitter price target lowered to $83 from $95 at MKM Partners
04/30/21 JPMorgan
Twitter earnings selloff a buying opportunity, says JPMorgan
04/30/21 Morgan Stanley
Twitter price target lowered to $62 from $68 at Morgan Stanley
X U.S. Steel
/

+

05/04/21 Credit Suisse
U.S. Steel upgraded to Outperform from Underperform at Credit Suisse
04/09/21 Goldman Sachs
U.S. Steel initiated with a Neutral at Goldman Sachs
03/15/21
Fly Intel: Top five analyst downgrades
03/15/21 BMO Capital
U.S. Steel price target raised to $25 from $21 at BMO Capital
SQQQ ProShares UltraPro Short QQQ
/

+

YUM Yum! Brands
/

+

X U.S. Steel
/

+

UNVR Univar
/

+

TWTR Twitter
/

+

TDOC Teladoc
/

+

RKT Rocket Companies
/

+

PFE Pfizer
/

+

CLF Cleveland-Cliffs
/

+

  • 09
    Feb
  • 03
    Feb
  • 06
    Aug
  • 18
    Jun
YUM Yum! Brands
/

+

X U.S. Steel
/

+

TWTR Twitter
/

+

TDOC Teladoc
/

+

RKT Rocket Companies
/

+

PFE Pfizer
/

+

YUM Yum! Brands
/

+

X U.S. Steel
/

+

TWTR Twitter
/

+

TDOC Teladoc
/

+

RKT Rocket Companies
/

+

PFE Pfizer
/

+

CLF Cleveland-Cliffs
/

+

X U.S. Steel
/

+

TWTR Twitter
/

+

TDOC Teladoc
/

+

SQQQ ProShares UltraPro Short QQQ
/

+

RKT Rocket Companies
/

+

PFE Pfizer
/

+

CLF Cleveland-Cliffs
/

+

ATOS Atossa Therapeutics
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.